Effect of Chinese medicine prescription on nephrotic syndrome: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
26
6
2020
Statut:
ppublish
Résumé
Nephrotic syndrome (NS) is a common chronic recurrent kidney disease. Many trials have shown that Chinese medicine prescription (CMP) can effectively treat NS. The program aims to evaluate the efficacy and safety of CMP for NS. This systematic evaluation will entail an electronic and manual search of all CMP for NS from inception to February, 2020, regardless of the publication status or language. Databases include PubMed, Embase, Springer, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trial Registration Platform, the Chinese Medicine Database, the China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the China Science Journal Database, and the Wanfang Database. Other sources of information, including bibliographies and meeting minutes for identified publications, will also be searched. A manual search for grey literature, including unpublished conference articles will be performed. Additionally, any clinical randomized controlled trials related to CMP for NS, regardless of the publication status and language limitations, will be included in the study. Study selection, data extraction, and research quality assessments will be conducted independently by 2 researchers. The main result was the total clinical efficacy rate or other validated scales after at least 2 weeks of treatment. Secondary outcomes included 24-hour urine protein quantification, blood urea nitrogen, serum creatinine, C-reactive protein, tumor necrosis factor-α, and interleukin 6, recurrence rates and adverse events during follow-up. Implement the Cochrane RevMan V5.3 bias assessment tool to assess bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean difference, standard mean deviation and binary data will be used to represent continuous results. This study will provide a comprehensive review and evaluation of CMP for the treatment of NS. This study will provide new evidence for evaluating the effectiveness and side effects of CMP on NS. Since the data is not personalized, formal ethical approval is not required. INPLASY202040181.
Sections du résumé
BACKGROUND
BACKGROUND
Nephrotic syndrome (NS) is a common chronic recurrent kidney disease. Many trials have shown that Chinese medicine prescription (CMP) can effectively treat NS. The program aims to evaluate the efficacy and safety of CMP for NS.
METHODS
METHODS
This systematic evaluation will entail an electronic and manual search of all CMP for NS from inception to February, 2020, regardless of the publication status or language. Databases include PubMed, Embase, Springer, Web of Science, the Cochrane Library, the World Health Organization International Clinical Trial Registration Platform, the Chinese Medicine Database, the China National Knowledge Infrastructure, the Chinese Biomedical Literature Database, the China Science Journal Database, and the Wanfang Database. Other sources of information, including bibliographies and meeting minutes for identified publications, will also be searched. A manual search for grey literature, including unpublished conference articles will be performed. Additionally, any clinical randomized controlled trials related to CMP for NS, regardless of the publication status and language limitations, will be included in the study. Study selection, data extraction, and research quality assessments will be conducted independently by 2 researchers. The main result was the total clinical efficacy rate or other validated scales after at least 2 weeks of treatment. Secondary outcomes included 24-hour urine protein quantification, blood urea nitrogen, serum creatinine, C-reactive protein, tumor necrosis factor-α, and interleukin 6, recurrence rates and adverse events during follow-up. Implement the Cochrane RevMan V5.3 bias assessment tool to assess bias risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). Mean difference, standard mean deviation and binary data will be used to represent continuous results.
RESULTS
RESULTS
This study will provide a comprehensive review and evaluation of CMP for the treatment of NS.
CONCLUSION
CONCLUSIONS
This study will provide new evidence for evaluating the effectiveness and side effects of CMP on NS. Since the data is not personalized, formal ethical approval is not required.
INPLASY REGISTRATION NUMBER
UNASSIGNED
INPLASY202040181.
Identifiants
pubmed: 32502039
doi: 10.1097/MD.0000000000020622
pii: 00005792-202006050-00077
pmc: PMC7306324
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e20622Références
BMJ. 2008 May 24;336(7654):1185-9
pubmed: 18497417
Phytother Res. 2012 Jun;26(6):892-8
pubmed: 22086717
Clin Exp Nephrol. 2016 Jun;20(3):342-70
pubmed: 27099136
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Toxicology. 2006 Feb 1;218(2-3):164-71
pubmed: 16325981
J Tradit Chin Med. 2013 Jun;33(3):349-54
pubmed: 24024331
Kidney Int. 2017 Jul;92(1):21-23
pubmed: 28646993
Clin J Am Soc Nephrol. 2012 Mar;7(3):513-20
pubmed: 22344511
Phytother Res. 2010 Dec;24(12):1886-92
pubmed: 21043035
Lancet. 2005 Jan 22-28;365(9456):331-40
pubmed: 15664230
Int Immunol. 2020 Apr 12;32(4):283-292
pubmed: 31954058
Nephrology (Carlton). 2013 Jul;18(7):483-4
pubmed: 23782234
Cochrane Database Syst Rev. 2013 Jun 05;(6):CD006335
pubmed: 23740567
J Steroid Biochem Mol Biol. 2020 Feb;196:105490
pubmed: 31586640
J Clin Epidemiol. 2009 Oct;62(10):e1-34
pubmed: 19631507
Front Pharmacol. 2019 Oct 22;10:1261
pubmed: 31695617
Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i22-i29
pubmed: 28391348
J Ethnopharmacol. 2014 Feb 12;151(3):1124-1132
pubmed: 24389029
Am Fam Physician. 2016 Mar 15;93(6):479-85
pubmed: 26977832
J Tradit Chin Med. 2008 Mar;28(1):46-8
pubmed: 18416084
J Biol Regul Homeost Agents. 2019 Sep-Oct;33(5 Suppl. 1):13-18. Special Issue: Focus on Pediatric Nephrology
pubmed: 31630708
J Ren Care. 2020 Mar;46(1):45-51
pubmed: 31746128
Minerva Med. 2013 Jun;104(3):333-47
pubmed: 23748287
J Am Soc Nephrol. 2013 Jan;24(1):7-9
pubmed: 23243214